ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV

The Defense Logistics Agency has awarded a firm-fixed-price delivery order, SPE2DP26F7486, to Teva Pharmaceuticals USA, Inc. (CAGE 3V8D7), for the procurement of 36,000 units of Adenovirus Type 4 and Type 7 Vaccine, Live, identified by NSN 6505016420106 and NDC 51285-0138-50, at a total contract value of $687,052.80. The order, issued under the basic contract SPE2DP20D0002, requires sole delivery by July 21, 2026, to FOB destination locations including Fort Detrick, Maryland, and JBSA Lackland, Texas, with no flexibility in quantity or pricing as the variance is set at zero percent. Teva is designated as a Small Business and specifically certified as a Women-Owned Small Business, triggering compliance with FAR 52.219-3, FAR 52.219-4, and FAR 52.219-15, which impose reporting and eligibility requirements. The vaccine must be shipped by the fastest traceable means, excluding parcel post, with each package marked with the "MARK FOR" identifier W25MWY and a unique Tracking Control Number, and delivered to a designated government point of contact at the destination where formal inspection and acceptance will be conducted by the government. Payment will be processed through the DLA payment office in Columbus, Ohio, under code SL4701, with invoicing required to comply with DFARS 252.232-7003, implying electronic submission via systems such as WAWF. The contracting officer is Melissa Rios Thomas, with Mark C. Lugo designated as the receiving official, while no contracting officer representative or contract specialist is formally named. No specific technical, preservation, packaging, or labeling standards beyond traceability and marking are detailed, and no additional special contract requirements, evaluation factors, or attachments are formally documented in the award notice.